Skip to main content
. 2014 May 16;4:110. doi: 10.3389/fonc.2014.00110

Figure 3.

Figure 3

Overall survival after stage IV diagnosis in patients not receiving ipilimumab treatment is not different in patients with serum sCTLA4 levels above 200 pg/mL. Overall survival curves (up to 5 years) of patients who did not receive ipilumumab comparing those with greater than 200 pg/mL serum sCTLA4 to those with less than or equal to 200 pg/mL.